Biomarker discovery and validation are necessary for improving the prediction of clinical
outcomes and patient monitoring. Despite considerable interest in biomarker discovery and …

Depression is caused by a change in neural activity resulting from an increase in glutamate
that drives excitatory neurons and may be responsible for the decline in the activity and …

Late-life depression is associated with significant cognitive impairment. Meta-analyses
showed that depression is associated with an increased risk for Alzheimer's disease (AD) …

Background Selective serotonin reuptaker inhibitors, including fluoxetine, are widely studied
and prescribed antidepressants, while their exact molecular and cellular mechanism are yet …

Schizophrenia (SCZ) is a chronic psychotic disorder that contributes significantly to
disability, affecting behavior, thought, and cognition. It has long been known that there is a …

Depression is a complex psychiatric disturbance involving many environmental, genetic,
and epigenetic factors. Until now, genetic, and non-genetic studies are still on the way to …

Neuropeptides are auxiliary messenger molecules that always co-exist in nerve cells with
one or more small molecule (classic) neurotransmitters. Neuropeptides act both as …

Non-invasive peripheral biomarkers play a significant role in both disease diagnosis and
progression. In the past few years, microRNA (miRNA) expression changes in circulating …

Major depressive disorder (MDD) is a common mental disorder generally characterized by
symptoms associated with mood, pleasure and effectiveness in daily life activities. MDD is …

Epigenetic mechanisms, such as alterations in histone acetylation based on histone
deacetylases (HDACs) activity, have been linked not only to normal brain function but also to …